PureTech launches phase II ‘long COVID’ drug trial
LYT-100 will be evaluated in patients with persistent symptoms caused by COVID-19
Read More
Tag: LYT-100
PureTech advances experimental COVID-19 drug into global trials
LYT-100 employs a multimodal mechanism of action to potentially reduce, delay or prevent the lung dysfunction documented in COVID-19 patients
Read More
First patient dosed in potential lymphoedema treatment trial
The drug being evaluated is an oral, small molecule drug candidate known as deupirfenidone.
Read More
PureTech acquires LYT-100 to treat lymphedema
The candidate, LYT-100, demonstrated anti-fibrotic and anti-inflammatory mechanisms in pre-clinical studies.
Read More
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
